Propofol is a commonly used intravenous anesthetic, popular for its rapid onset and effectiveness in inducing sedation and analgesia. However, one of the challenges associated with propofol administration is propofol injection pain. This discomfort, which occurs in 28%–90% of patients according to studies of different patient groups,1 can be distressing and complicates the overall experience of medical procedures. Several different factors, such as pharmacodynamics, the rate of injection, and patient-specific variables, can all play significant roles in the intensity and frequency of propofol injection pain. Understanding the mechanisms underlying this pain is crucial for improving surgical flow and patient outcomes in clinical settings.
A 2008 study found transient receptor potential ankyrin 1 (TRPA1), a nonselective ligand-gated cation channel, is heavily involved in the activation of peripheral nerve endings by general anesthetics, including propofol. TRPA1 is an ion channel on cell plasma membranes that is associated with pain perception; it is known as a biological sensor for chemical irritants, oxidative stress, and colder temperatures. In wild-type mice, propofol was shown to produce pain-related behaviors. In contrast, nocifensive behavior was absent in TRPA1–/− mice, but not in TRPA1+/− littermates. Propofol, when injected into the femoral artery, evoked reflex muscle activity in TRPA1+/− but not in their TRPA1–/− counterparts. These results indicate having one allele of the TRPA1 gene is sufficient for propofol-induced injection pain.2
A later study found another potential causative agent: transient receptor ankyrin vanilloid 1 (TRPV1), the excitatory ion channel of the transient receptor potential family that is activated by noxious stimuli such as capsaicin, protons, and excessive heat. The study, performed on human cell TRPA1 and TRPV1, revealed the two molecules mediate propofol-induced injection pain through increasing calcium ions in the dorsal root ganglion.3 This molecular release induces vascular leakage and is thought to contribute to neurogenic inflammation in the periphery and central sensitization in the spinal dorsal horn.1
The speed of injection and site of administration are also factors influencing propofol injection pain. Slow injection causes more pain than rapid bolus since slow injection increases the concentration and duration of exposure of propofol to the vein wall, while rapid injection quickly clears the drug from the vein and replaces it with blood.4 It is suggested the painful sensation originates from neural elements within the vein wall by way of free afferent nerve endings. Propofol
administration can release kininogen, the precursor to bradykinin, which supports vasodilation and hyper-permeability. Prolonged propofol administration may increase interaction between the drug and bradykinin, causing pain, swelling, and inflammation.5 In a prospective cohort study where patients were separated by age and gender, male subjects receiving propofol through the top of the hand were much less likely to experience propofol injection pain than their female counterparts (45.7% vs 74%). However, all groups demonstrated a significant decrease in propofol injection pain when the site of administration changed from the dorsum of hand to the antecubital fossa, i.e., the inside of the elbow (12.5% for men and 37% for women).6
While propofol remains a widely used and highly effective anesthetic, propofol injection pain is an important side effect to research and address in order to improve patient comfort. The multifaceted nature of propofol injection pain, involving both pharmacological and procedural factors, underscores the complexity and necessity of managing this side effect. Although there has been some research conducted to identify key contributors to this pain, it remains an area that requires deeper investigation. Additionally, much of the research to date is based on older datasets, highlighting the need for more contemporary studies to build on earlier findings.
References
1. Desousa, Kalindi A., “Pain on Propofol Injection: Causes and Remedies.” Indian Journal of Pharmacology, vol. 48, no. 6, 2016, p. 617. https://doi.org/10.4103/0253-7613.194845
2. Matta, José A., et al. “General Anesthetics Activate a Nociceptive Ion Channel to Enhance Pain and Inflammation.” Proceedings of the National Academy of Sciences, vol. 105, no. 25, June 2008, pp. 8784–89. https://doi.org/10.1073/pnas.0711038105
3. Fischer, Michael J. M., et al. “The General Anesthetic Propofol Excites Nociceptors by Activating TRPV1 and TRPA1 Rather than GABAA Receptors.” The Journal of Biological Chemistry, vol. 285, no. 45, Sept. 2010, p. 34781. https://doi.org/10.1074/jbc.M110.143958
4. Scott, R. P., et al. “Propofol: Clinical Strategies for Preventing the Pain of Injection.” Anaesthesia, vol. 43, no. 6, June 1988, pp. 492–94. https://doi.org/10.1111/j.1365-2044.1988.tb06641.x
5. Leff, Phillip J., et al. “Characteristics That Increase the Risk for Pain on Propofol Injection.” BMC Anesthesiology, vol. 24, no. 1, May 2024, p. 190. https://doi.org/10.1186/s12871-024-02573-y.
6. Kang, Hye-Joo, et al. “Clinical Factors Affecting the Pain on Injection of Propofol.” Korean Journal of Anesthesiology, vol. 58, no. 3, Mar. 2010, pp. 239–43. https://doi.org/10.4097/kjae.2010.58.3.239